Esperion Therapeutics reported $800K in Interest Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Alnylam Pharmaceuticals ALNY:US USD 7.82M 5.92M
Biogen BIIB:US USD 23.9M 11.3M
BioMarin Pharmaceutical BMRN:US USD 5M 2.49M
Cytokinetics CYTK:US USD 4.14M 3.28M
Esperion Therapeutics ESPR:US USD 800K 400K
Geron GERN:US USD 852K 522K
Intra Cellular Therapies ITCI:US USD 2.12M 802K
Moderna Inc MRNA:US USD 58M 18M
Nektar Therapeutics NKTR:US USD 2.05M 954K
Pfizer PFE:US USD 137M 67M
Puma Biotechnology PBYI:US USD 216K 151K
Sarepta Therapeutics SRPT:US USD 4.78M 2.37M
United Therapeutics UTHR:US USD 13.3M 6.5M